Mechanism of mycobacterial ATP synthase inhibition by squaramides and second generation diarylquinolines
The EMBO Journal · 2023
DOI: 10.15252/embj.2023113687 ↗Kurz gefasst
Fachartikel in der Zeitschrift The EMBO Journal, 2023. Verfasst von Gautier M Courbon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Medicine Program, The Hospital for Sick Children, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Diarylquinolines, Mycobacterium tuberculosis. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR, Canada Research Chairs, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Mycobacteria, such as Mycobacterium tuberculosis, depend on the activity of adenosine triphosphate (ATP) synthase for growth. The diarylquinoline bedaquiline (BDQ), a mycobacterial ATP synthase inhibitor, is an important medication for treatment of drug-resistant tuberculosis but suffers from off-target effects and is susceptible to resistance mutations. Consequently, both new and improved mycobacterial ATP synthase inhibitors are needed. We used electron cryomicroscopy and biochemical assays to study the interaction of Mycobacterium smegmatis ATP synthase with the second generation diarylquinoline TBAJ-876 and the squaramide inhibitor SQ31f. The aryl groups of TBAJ-876 improve binding compared with BDQ, while SQ31f, which blocks ATP synthesis ~10 times more potently than ATP hydrolysis, binds a previously unknown site in the enzyme's proton-conducting channel. Remarkably, BDQ, TBAJ-876, and SQ31f all induce similar conformational changes in ATP synthase, suggesting that the resulting conformation is particularly suited for drug binding. Further, high concentrations of the diarylquinolines uncouple the transmembrane proton motive force while for SQ31f they do not, which may explain why high concentrations of diarylquinolines, but not SQ31f, have been reported to kill mycobacteria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Medicine Program, The Hospital for Sick Children, Toronto, ON, Canada.
- Department of Medical Biophysics, The University of Toronto, Toronto, ON, Canada.
- Institut für Pharmazie, Martin-Luther-Universität Halle-Wittenberg, Halle, Saale, Germany.
- Department of Biochemistry, The University of Toronto, Toronto, ON, Canada.
ORCID-Profile: Peter Imming, John L Rubinstein
Förderung
- CIHR
- Canada Research Chairs
- Deutsche Forschungsgemeinschaft
- Gouvernement du Canada | Canadian Institutes of Health Research
- Ontario Graduate Scholarship
Zitieren
APA
Courbon, G. M., Palme, P. R., Mann, L., Richter, A., Imming, P., & Rubinstein, J. L. (2023). Mechanism of mycobacterial ATP synthase inhibition by squaramides and second generation diarylquinolines. The EMBO Journal. https://doi.org/10.15252/embj.2023113687
Vancouver
Courbon GM, Palme PR, Mann L, Richter A, Imming P, Rubinstein JL. Mechanism of mycobacterial ATP synthase inhibition by squaramides and second generation diarylquinolines. The EMBO Journal. 2023. doi:10.15252/embj.2023113687
BibTeX
@article{Courbon2023,
author = {Courbon, Gautier M and Palme, Paul R and Mann, Lea and Richter, Adrian and Imming, Peter and Rubinstein, John L},
title = {Mechanism of mycobacterial ATP synthase inhibition by squaramides and second generation diarylquinolines},
journal = {The EMBO Journal},
year = {2023},
doi = {10.15252/embj.2023113687}
}
EUVIMED